Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma

  • Authors:
    • Murat Elli
    • Sema Yilmaz
    • Ramazan Aydin
    • Sadriye Murat
    • Meltem Ceyhan Bilgici
    • Ayhan Dagdemir
  • View Affiliations

  • Published online on: March 5, 2013     https://doi.org/10.3892/mco.2013.88
  • Pages: 550-552
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Relapsed or refractory B‑cell non‑Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti‑CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab.
View Figures
View References

Related Articles

Journal Cover

May-June 2013
Volume 1 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Elli M, Yilmaz S, Aydin R, Murat S, Bilgici MC and Dagdemir A: Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma. Mol Clin Oncol 1: 550-552, 2013
APA
Elli, M., Yilmaz, S., Aydin, R., Murat, S., Bilgici, M.C., & Dagdemir, A. (2013). Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma. Molecular and Clinical Oncology, 1, 550-552. https://doi.org/10.3892/mco.2013.88
MLA
Elli, M., Yilmaz, S., Aydin, R., Murat, S., Bilgici, M. C., Dagdemir, A."Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma". Molecular and Clinical Oncology 1.3 (2013): 550-552.
Chicago
Elli, M., Yilmaz, S., Aydin, R., Murat, S., Bilgici, M. C., Dagdemir, A."Rituximab used in three cases with relapsed non‑Hodgkin's lymphoma". Molecular and Clinical Oncology 1, no. 3 (2013): 550-552. https://doi.org/10.3892/mco.2013.88